Final verdict
I am closing Cortexin as successful. The effect I was looking for was not a stimulant rush or a faster button press. It was a reduction in cognitive friction: thoughts felt clearer, mental work felt easier to engage with, and that quality remained present after the final administration.
The objective vigilance test did not improve. That makes the result narrower, but it does not erase the repeated subjective outcome. Cortexin succeeded for felt cognitive quality and effort, not for reaction speed.
The question
Would a ten-day Cortexin course produce a clear and repeatable improvement in morning mental clarity, alertness, sustained focus, cognitive fatigue, mood stability, or stress tolerance, and would the pattern differ meaningfully from my completed Cerebrolysin experiment?
Protocol as run
I used 10 mg intramuscularly once daily for ten consecutive days, September 22 through October 1, 2026. Total exposure was 100 mg. The first morning measurement was completed before the first dose and remained a separate pre-dose anchor. Nine subsequent course mornings represented prior-day exposure. No-dose follow-up continued through October 8.
Measurement structure
The formal baseline contained seven complete mornings. Every morning measurement was intended to occur shortly after waking and before Bromantane, caffeine, pre-workout, food, training, or that day's Cortexin administration.
Each morning included mental clarity, alertness/energy, mood, sleep inertia, sleep duration and efficiency, resting heart rate, HRV, headache, dizziness, nausea, agitation, unusual feelings, and a fixed three-minute psychomotor-vigilance test. Injection pain and immediate reactions were recorded after every administration.
Headline results
| Phase | Mornings | Clarity | Alertness | Mood | PVT mean | Lapses | Sleep |
|---|---|---|---|---|---|---|---|
| Baseline | 7 | 7/10 | 7/10 | 7/10 | 348.11 ms | 3.73% | 5 h 41 m |
| Day 1 pre-dose | 1 | 8/10 | 7/10 | 8/10 | 353.80 ms | 0% | 5 h 22 m |
| Exposed mornings | 9 | 9/10 | 8/10 | 8/10 | 352.18 ms | 1.89% | 5 h 11 m |
| No-dose follow-up | 5 | 9/10 | 9/10 | 9/10 | 358.52 ms | 4.10% | 4 h 03 m |
Subjective values are phase medians. PVT and sleep values are means. Day 1 is shown separately because its test preceded the first administration.
The felt cognition result
Baseline clarity, alertness, and mood medians were 7/10, 7/10, and 7/10. Across Days 2 through 10, after exposure had begun, the medians were 9/10, 8/10, and 8/10. Clarity reached 9/10 on five of the nine exposed mornings, exactly meeting the planned threshold of a two-point improvement on at least five mornings.
The useful distinction was qualitative. I did not feel acutely stimulated. Cognition felt cleaner and required less effort. That is the result I would carry forward from this experiment.
What PVT measured
PVT stands for Psychomotor Vigilance Task. I used the same three-minute morning test to measure sustained attention and simple visual reaction speed. Each day's analysis retained responses of 500 ms or longer as lapses. A response below 100 ms counted as a false start and was excluded from the separate analysis mean. I did not repeat a disappointing session.
PVT does not directly measure mental clarity, reasoning, creativity, memory, or how effortful cognition feels. It gave the experiment an objective test of one narrower question: did vigilance become faster?
The objective PVT result
The answer was no. Baseline PVT averaged 348.11 ms. The nine exposed mornings averaged 352.18 ms, only 4.07 ms slower and effectively flat for this experiment. Follow-up averaged 358.52 ms. The planned improvement threshold was 336.87 ms, and only one of the final five active mornings and one of the five comparable follow-up mornings crossed it.
Lapse rate did improve during the course, from 3.73% at baseline to 1.89%, but it rose to 4.10% in follow-up. That secondary pattern was not persistent enough to count as an objective vigilance success.
Persistence after the course
The subjective result remained visible after dosing ended. Across five comparable follow-up mornings, clarity, alertness, and mood all had medians of 9/10. Clarity was 9/10 on four of those five mornings, and alertness was 9/10 on three.
A later final review recorded clarity 9/10, useful sustained focus 8/10, cognitive fatigue 3/10, practical productivity 9/10, mood stability 9/10, and emotional control 8/10. It was collected outside the original end-of-day window, so I treat it as supporting context rather than a replacement for the missed scheduled check.
Why I call this successful
- Mental clarity improved by the planned two points on five exposed mornings.
- The subjective improvement persisted across multiple no-dose follow-up mornings.
- Alertness and mood moved in the same useful direction.
- The change was functional and course-level, not an immediate injection sensation.
- No unacceptable systemic, cardiovascular, neurological, or injection-site cost appeared.
The original scorecard also asked PVT to confirm the result. It did not. I am therefore not calling Cortexin a broad cognitive enhancer. I am calling the observed outcome successful for the narrower result that actually emerged: improved felt quality and effort of cognition.
Injection tolerability
| Days | Administration range | Immediate pain | Immediate reaction |
|---|---|---|---|
| 1 to 5 | 11:00 AM to 6:00 PM | 0 to 4/10 | No immediate reaction |
| 6 to 10 | 10:30 AM to 1:25 PM | 0/10 | No immediate reaction |
All ten planned administrations were completed. Maximum immediate pain was 4/10 on Day 3. Pain was 0/10 on the final five injections. No immediate reaction was reported, and no progressive local problem emerged.
Symptoms, cardiovascular measures, and sleep
Headache, dizziness, nausea, and agitation were all zero on every recorded active and comparable follow-up morning. Resting heart rate was essentially unchanged, averaging 62.29 bpm at baseline and 62.22 bpm during exposure. HRV averaged 44.57 ms at baseline and 46.00 ms during exposure. The six collected blood-pressure readings did not show a concerning symptom pattern, although the planned Day 5 and Day 10 pairs were missed.
Mean sleep duration declined from 5 hours 41 minutes at baseline to 5 hours 11 minutes during exposure. Sleep efficiency, resting heart rate, HRV, and morning symptoms did not show a matching deterioration. I did not observe a sleep benefit from Cortexin.
What did not produce a clear result
Reaction speed did not improve. Sleep did not improve. Resting heart rate, HRV, and blood pressure did not show a useful course-level change. Same-day post-dose and midday checks were too sparse to establish a reliable acute-response curve. The strongest evidence is the repeated morning clarity pattern and its persistence.
How Cortexin compared with Cerebrolysin
Cerebrolysin remains the stronger and broader personal result. It produced a larger improvement in clarity and energy from a lower starting point, followed by a distinctive improvement in emotional regulation. Cortexin produced a narrower result centered on mental clarity, alertness, mood, and lower felt cognitive effort.
Cortexin was much easier to tolerate locally. Its maximum immediate pain was 4/10 and the final five injections were painless. Cerebrolysin involved substantially more pain, pressure, stiffness, brief spasms, and minor bleeding. Cortexin also included daily PVT, which showed that the subjective benefit did not translate into faster reaction time. Cerebrolysin did not have that objective test.
Both experiments felt more like a gradual shift than an immediate rush. Cerebrolysin had the more consequential overall payoff. Cortexin had the cleaner administration experience and the more specific result: cognition felt better without becoming measurably faster.
Interpretation
The central finding is the separation between subjective cognition and psychomotor vigilance. If Cortexin helped, it changed how clear and effortful cognition felt rather than the speed of a simple visual response. The persistence after the course makes a momentary injection sensation an unlikely explanation for the whole pattern.
The result should be kept at that level. This experiment did not measure neuroprotection, memory formation, learning, or structural brain change. It measured a repeatable personal improvement in felt cognitive quality, plus a separate objective test that remained flat.
What I would change in a future repeat
- Use blinded or randomized on/off periods.
- Collect matched baseline focus and cognitive-fatigue ratings.
- Complete every planned same-day and end-of-day check.
- Keep one PVT application, device, and setting for every morning.
- Use a fixed administration time.
Final decision
The experiment is closed as a success for improved felt quality and effort of cognition. The clearest benefit was mental clarity. The effect repeated, persisted after dosing, and came without an unacceptable tolerability cost. Cortexin did not improve objective vigilance, so that claim is not part of the result.